Pila Pharma Is A Swedish Biotech Company Based In Malma Specializing In The Development Of Trpv1 Antagonistsits Lead Candidatexen D0501Is Being Explored As A Treatment For Type 2 Diabetes And Other Inflammatory Diseasesthe Company Was Listed On The Nasdaq First North Growth Market In Stockholm On July 152021 Xen D0501 Has Shown Promise In Clinical Trialsdemonstrating Safety In Studies With Up To 300 Subjects And A Significant Effect On Insulin Release And Glucose Tolerance In Diabetic Patientspila Pharma Is Currently Conducting Phase 2 Clinical Trials For This Compoundwhich Is Also Being Investigated For Potential Benefits In Cardiovascular Diseases And Obesitythe Company Aims To Secure Partnerships To Advance Its Research And Development Effortsfocusing On Bringing Xen D0501 To Proof Of Concept For Treating Cardiometabolic Conditions
No conferences found for this company.
| Company Name | Pila Pharma Ab |
| Country |
Sweden
|
| Address | N/A |
| Telephone | N/A |
| N/A |
